Advertisement

Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer

  • Isaac A. Bowman
    Affiliations
    Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
    Search for articles by this author
  • Ivan Pedrosa
    Affiliations
    Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX

    Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX

    Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
    Search for articles by this author
  • Payal Kapur
    Affiliations
    Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX

    Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX
    Search for articles by this author
  • James Brugarolas
    Correspondence
    Address for correspondence: James Brugarolas, MD, PhD, Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390
    Affiliations
    Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

    Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
    Search for articles by this author
Published:February 06, 2017DOI:https://doi.org/10.1016/j.clgc.2017.01.026

      Abstract

      Introduction

      The development of a second primary malignancy in a patient with a preexisting diagnosis of metastatic cancer may be easily overlooked or misattributed to progression of disease. We report 3 patients with clear-cell renal cell carcinoma (RCC) metastatic to the lungs who were subsequently diagnosed with non–small-cell lung cancer (NSCLC). We examined the frequency of this occurrence within our institution and report on the radiographic findings that may help distinguish between metastatic RCC and primary lung cancers.

      Methods

      Patients who received systemic targeted therapy for metastatic RCC at our institution between January 2006 and October 2013 were identified, and the proportion and incidence rate for developing NSCLC with preexisting metastatic RCC were calculated.

      Results

      Two percent (3/151; 95% confidence interval [CI], 0.68%-5.68%) of patients treated for metastatic RCC with systemic targeted therapies at our institution were subsequently diagnosed with NSCLC, increasing to 3.5% (3/85; 95% CI, 1.21%-9.87%) among patients with known RCC pulmonary metastasis. The incident rate for development of NSCLC in patients with metastatic RCC was 0.87 per 100 person-years (95% CI, 0.22-2.4).

      Conclusion

      The subsequent diagnosis of a primary lung cancer in metastatic RCC patients occurred in 2% of patients at our institution and is underreported in the literature. Primary NSCLC may be underdiagnosed in patients with metastatic RCC. Both the radiographic appearance and clinical behavior of a lesion may hold clues that can help distinguish between a new primary and progression of metastatic disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Surveillance, Epidemiology, and End Results (SEER) Program Stat Fact Sheet: Kidney and Renal Pelvis Cancer. National Cancer Institute. Available at: http://seer.cancer.gov/statfacts/html/kidrp.html. Accessed: April 14, 2016.

        • Motzer R.J.
        • Escudier B.
        • McDermott D.F.
        • et al.
        Nivolumab versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1803-1813
        • Motzer R.J.
        • Mazumdar M.
        • Bacik J.
        • et al.
        Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
        J Clin Oncol. 1999; 17: 2530-2540
        • Heng D.Y.
        • Xie W.
        • Regan M.M.
        • et al.
        Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
        J Clin Oncol. 2009; 27: 5794-5799
        • Newcombe R.G.
        Two-sided confidence intervals for the single proportion: comparison of seven methods.
        Stat Med. 1998; 17: 857-872
      2. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 3. Available at: www.OpenEpi.com, updated April 2013. Accessed: January 13, 2017.

        • Griffin N.
        • Gore M.E.
        • Sohaib S.A.
        Imaging in metastatic renal cell carcinoma.
        AJR Am J Roentgenol. 2007; 189: 360-370
        • Bianchi M.
        • Sun M.
        • Jeldres C.
        • et al.
        Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.
        Ann Oncol. 2012; 23: 973-980
        • Cooke D.T.
        • Zheng D.J.
        • Peterson K.A.
        • et al.
        Synchronous pulmonary renal cell carcinoma metastases and primary non-small cell lung cancer.
        J Thorac Oncol. 2010; 5: 140-141
        • Shiraishi Y.
        • Nakajima Y.
        • Katsuragi N.
        • et al.
        Kyobu Geka. 2003; 56: 47-50
        • Rabbani F.
        • Grimaldi G.
        • Russo P.
        Multiple primary malignancies in renal cell carcinoma.
        J Urol. 1998; 160: 1255-1259
        • Beisland C.
        • Talleraas O.
        • Bakke A.
        • et al.
        Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study.
        BJU Int. 2006; 97: 698-702
        • Liu H.
        • Hemminki K.
        • Sundquist J.
        Renal cell carcinoma as first and second primary cancer: etiological clues from the Swedish Family-Cancer Database.
        J Urol. 2011; 185: 2045-2049
        • Hirakata K.
        • Nakata H.
        • Haratake J.
        Appearance of pulmonary metastases on high-resolution CT scans: comparison with histopathologic findings from autopsy specimens.
        AJR Am J Roentgenol. 1993; 161: 37-43
        • Zwirewich C.V.
        • Vedal S.
        • Miller R.R.
        • et al.
        Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation.
        Radiology. 1991; 179: 469-476
        • Truong M.T.
        • Sabloff B.S.
        • Ko J.P.
        Multidetector CT of solitary pulmonary nodules.
        Thorac Surg Clin. 2010; 20: 9-23
        • Burns J.
        • Haramati L.B.
        • Whitney K.
        • et al.
        Consistency of reporting basic characteristics of lung nodules and masses on computed tomography.
        Acad Radiol. 2004; 11: 233-237
        • Jacobs C.
        • van Rikxoort E.M.
        • Murphy K.
        • et al.
        Computer-aided detection of pulmonary nodules: a comparative study using the public LIDC/IDRI database.
        Eur Radiol. 2016; 26: 2139-2147
        • Perandini S.
        • Soardi G.A.
        • Motton M.
        • et al.
        Solid pulmonary nodule risk assessment and decision analysis: comparison of four prediction models in 285 cases.
        Eur Radiol. 2016; 26: 3071-3076
        • Tsivian M.
        • Moreira D.M.
        • Caso J.R.
        • et al.
        Cigarette smoking is associated with advanced renal cell carcinoma.
        J Clin Oncol. 2011; 29: 2027-2031